polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors
Roots Analysis is pleased to announce the publication of its recent study, titled, “Polycystic Ovary Syndrome Market, 2021-2031.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products.
Detailed profiles of the players that are engaged in the development of drug products / therapies for polycystic ovarian syndrome.
An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III).
A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs.
An insightful analysis of the patents filed / granted for polycystic ovary syndrome, since 2016, taking into consideration various parameters.
An in-depth analysis of grants awarded to various research institutes for the projects related to polycystic ovary syndrome, in the period between 2016 and April 2021.
A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Insulin Sensitizing Agents
Route of Administration
North America (US, Canada)